Literature DB >> 8814686

Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer.

E Roca1, E Pennella, M Sardi, S Carraro, M Barugel, C Milano, A Fiorini, R Giglio, G Gonzalez, R Kneitschel, E Aman, A Jarentchuk, C Blajman, J Nadal, M T Santarelli, A Navigante.   

Abstract

From January 1990 to April 1993, 60 oesophageal cancer patients were enrolled in a protocol of non-surgical treatment that consisted of induction chemotherapy followed by concurrent chemoradiotherapy. Induction chemotherapy consisted of cisplatin 40 mg/m2 intravenous bolus days 1, 2, 14, 15; 24 h continuous infusion of 5-fluorouracil (5-FU) 1000 mg/m2 days 1 and 14; leucovorin 20 mg/m2 days 1 and 14 given before and with 5-FU; bleomycin 30 UI days 1 and 14; mitomycin C 10 mg/m2 day 14. Concurrent chemoradiotherapy consisted of 60 Gy (6 weeks) from day 21 and cisplatin 70 mg/m2 days 28, 42 and 56; leucovorin 20 mg/m2 followed by 5-FU 425 mg/m2 days 28, 35, 42, 49 and 56. Complete response occurred in 44 of 55 evaluable patients (80%). The median survival is 32 months; the actuarial survival at 40 months is 35% (CI 18-53). These results appear improved over those reported with surgery or radiation alone, and suggest that organ preservation as a secondary treatment goal should be vigorously investigated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814686     DOI: 10.1016/0959-8049(95)00524-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  2 in total

1.  Late course accelerated hyperfractionated radiotherapy for clinical T1-2 esophageal carcinoma.

Authors:  Kuai-Le Zhao; Yang Wang; Xue-Hui Shi
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

2.  Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer.

Authors:  T Conroy; F Viret; E François; J F Seitz; V Boige; M Ducreux; M Ychou; J P Metges; M Giovannini; Y Yataghene; D Peiffert
Journal:  Br J Cancer       Date:  2008-10-07       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.